Part II: Leaders in healthcare marketing and communications discuss the looming concerns regarding the healthcare ecosystem.
Many biopharma companies raised funds in 2022, but not enough to reach their next milestone. Investors have been constricting investments, so companies needing additional funding require a larger toolbox.
Johnson & Johnson on Tuesday posted better than expected third-quarter earnings on strong demand for its cancer drug Darzalex, but said it may still cut some jobs as it contends with inflationary pressure and challenges created by the strong dollar.
As the economy ebbs and flows, pharma and biotech companies alike are feeling the pressure to cut costs. From rapid inflation to the ever-changing regulatory landscape, many are looking for ways to reduce their burn rate.
The United States is in the early days of a recession and the biotech industry is in a bit of a slump. CEOs can take heart, however, by applying the lessons of previous recessions to business today and understanding what is different about the current situation.